Thompson Siegel & Walmsley’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Thompson Siegel & Walmsley’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-150	Closed	-$8K	–	849
2017 Q4	$8K	Hold	150	–	–	﹤0.01%	752
2017 Q3	$9K	Sell	150 -114	-43%	-$6.68K	﹤0.01%	722
2017 Q2	$16K	Buy	264 +66	+33%	+$3.76K	﹤0.01%	672
2017 Q1	$11K	Buy	+198	New	+$9.75K	﹤0.01%	691

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Thompson Siegel & Walmsley's BIVV Position: Q1 2018 in Review

Thompson Siegel & Walmsley sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 150 shares — an estimated $8K sold.

Thompson Siegel & Walmsley first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $16K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Thompson Siegel & Walmsley reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Thompson Siegel & Walmsley sold 150 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $8K.
Thompson Siegel & Walmsley first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Thompson Siegel & Walmsley's Bioverativ Inc. Common Stock position peaked at $16K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2018, filed 8 May 2018.